- Conditions
- Heart Failure
- Interventions
- Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • Lake Forest, California • Santa Maria, California + 18 more
Condition Directory
Heart Failure clinical trials
Directory of U.S. ClinicalTrials.gov public records for Heart Failure. Browse Heart Failure recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 27, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
252
Shown on this page
12
Current sort
Recently updated
Condition scope
Heart Failure
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Heart Failure studies are organized in the registry
Heart failure records routinely distinguish reduced versus preserved ejection fraction — the abbreviations HFrEF and HFpEF appear directly in titles and condition fields and are the cleanest way to split the portfolio. Device and monitoring studies form a substantial share alongside drug trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 252 matching trials for Heart Failure.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- VS-041, Placebo
- Drug · Other
- Lead sponsor
- Vasa Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Huntington Beach, California • Santa Maria, California + 18 more
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
- Interventions
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Device
- Lead sponsor
- Impulse Dynamics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
- Interventions
- Individualized myPACE pacemaker programming
- Device
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Cardiovascular Diseases
- Interventions
- empagliflozin, Placebo tablet
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Resmetirom, Placebo
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Peoria, Arizona • Oxnard, California • Fort Myers, Florida + 2 more
- Conditions
- Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Placebo (matching), Beta-blockers
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Pleasanton, California
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 45
- States / cities
- Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
- Conditions
- Heart Failure With Preserved Ejection Fraction, Iron Deficiency
- Interventions
- Ferric derisomaltose, Placebo (normal saline)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
- Interventions
- Exogenous Ketone Drink, Placebo
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 30 Years to 84 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more
About this Heart Failure clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Heart Failure as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Heart Failure.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Heart Failure.